TEMTempus AI, Inc.
Price
-20%1YEnd-of-day closes, not the intraday tick.
More going right than wrong
Quality mixed, nothing alarming, growing in the filings, the market undecided.
Tempus is a technology company focused on healthcare that straddles two converging worlds. We strive to combine deep healthcare expertise, providing next-generation diagnostics across multiple disease areas, with leading technology capabilities, harnessing the power of data and analytics to help personalize medicine. Unlike traditional diagnostic labs, we can incorporate unique patient information, such as clinical, molecular, and imaging data, with the goal of making our tests more intelligent and our results more insightful.
In the company’s own words · 10-K filed Feb 24, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Tempus AI, Inc. (TEM) reported revenue of $382M in Q2 2026 (quarter ended Jun 30, 2026), up 22% from the same quarter a year earlier. That came with net income of $5.6M (1.5% of revenue). For the full year FY2025, revenue was $1.27B (+83% year on year) and net income −$245M. Its largest product in Q2 2026 was Clinical Order at $264M, 69% of the disclosed total, well ahead of Insights Product at 20%. The next results filing is expected around Nov 3, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Jul 30, 2026Tempus Reports Second Quarter 2026 Results.Earnings release · press release
- Jul 20, 2026On July 20, 2026, Tempus AI, Inc., a Nevada corporation (“Tempus”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) by and among Tempus, Personalis, Inc., a Delaware corporation (“Personalis”), Aviary Development, Inc., a Delaware corporation and a wholly-owned subsidiary of Tempus (“Merger Sub …Material agreement entered · Form 8-K
- Jul 20, 2026Tempus to Acquire Personalis, More Tightly Integrating Molecular Residual Disease (MRD) into Its AI-Enabled.Regulation FD disclosure · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $382.3MThe company’s own SEC segment disclosure.
- Clinical Order$264.4M69%
- Insights Product$77.7M20%
- Genomics Product$24.9M7%
- Trials Product$9.0M2%
- Next Product$6.3M2%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.
Health Information Services
Ranks #20 of 20 by RyuScore